Disc Medicine, Inc. (IRON)
| Market Cap | 2.99B +43.6% |
| Revenue (ttm) | n/a |
| Net Income | -245.89M |
| EPS | -6.56 |
| Shares Out | 38.39M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 142,266 |
| Open | 79.19 |
| Previous Close | 80.03 |
| Day's Range | 77.55 - 80.53 |
| 52-Week Range | 40.00 - 99.50 |
| Beta | 2.06 |
| Analysts | Strong Buy |
| Price Target | 101.58 (+30.35%) |
| Earnings Date | Jul 30, 2026 |
About IRON
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the tre... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for IRON stock is "Strong Buy." The 12-month stock price target is $101.58, which is an increase of 30.35% from the latest price.
News
Disc Medicine price target raised to $90 from $85 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $90 from $85 and keeps an Overweight rating on the shares.
Disc Medicine reports Q2 EPS ($1.54), consensus ($1.77)
“The anticipated readout of the Phase 3 APOLLO trial of bitopertin in EPP in Q4 marks a significant milestone. We have continued driving forward on this program over the past…
Disc Medicine Slides: Corporate presentation
Disc Medicine has posted slides in relation to its latest quarterly earnings report, which was published on July 30, 2026.
Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update
WATERTOWN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Earnings release: Q2 2026
Disc Medicine released its Q2 2026 earnings on July 30, 2026, summarizing the period's financial results.
Disc Medicine Quarterly report: Q2 2026
Disc Medicine has published its Q2 2026 quarterly earnings report on July 30, 2026.
Disc Medicine Transcript: AGM 2026
The meeting established a quorum and proceeded with director elections, a say-on-pay vote, and auditor ratification, all of which were approved by stockholders. No questions were raised, and final results will be filed with the SEC.
Disc Medicine price target raised to $85 from $80 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $85 from $80 and keeps an Overweight rating on the shares after the company hosted a call to…
Disc Medicine Transcript: Study update
Bitopertin's phase III APOLLO study is on track for top-line data in Q4, with sustained efficacy and safety seen in HELIOS. Selcodebart showed robust, durable anemia responses in MF across all subgroups, while DISC-3405 advances in PV and sickle cell disease, with initial data expected later this year.
Disc Medicine Press release: Study update
Disc Medicine issued a press release on June 15, 2026, disclosing material business information to investors.
Disc Medicine Slides: Study update
Disc Medicine has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting
WATERTOWN, Mass., June 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Provides Update from FDA Type A Meeting for Bitopertin in Erythropoietic Protoporphyria
WATERTOWN, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Transcript: Jefferies Global Healthcare Conference 2026
Key programs are advancing with pivotal data readouts and regulatory meetings expected by year-end. Bitopertin’s phase III trial in EPP is fully enrolled, with a differentiated mechanism targeting the root cause and commercial launch preparations underway.
Disc Medicine presents updated data from RALLY-MF trial at ASCO
Disc Medicine (IRON) presented updated data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASCO Annual Meeting in Chicago. In this updated data set,…
Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response was seen independent of concomitant JAK inhibitor the...
Disc Medicine Slides: Corporate presentation
Disc Medicine has posted slides in relation to its latest quarterly earnings report, which was published on June 2, 2026.
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Disc Medicine Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Enrollment in the APOLLO study for bitopertin surpassed expectations, highlighting strong demand and a larger-than-expected EPP patient population. Key pipeline updates include promising efficacy for DISC-0974 in myelofibrosis and strategic expansion into IBD and sickle cell disease.
Disc Medicine price target raised to $80 from $75 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Disc Medicine (IRON) to $80 from $75 and keeps an Overweight rating on the shares.
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress
WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...
Disc Medicine to Participate in Upcoming Investor Conferences
WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel t...
Disc Medicine reports Q1 EPS ($1.65), consensus ($1.73)
“We continue to make strong progress across the portfolio, completing enrollment in our Phase 3 trial of bitopertin in EPP and remaining on track to report topline data in the…
Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update
Completed enrollment of the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP); topline data expected in Q4 2026 Updated data from Phase 2 study of DISC-0974 in patients with an...
Disc Medicine Quarterly report: Q1 2026
Disc Medicine has published its Q1 2026 quarterly earnings report on May 5, 2026.